# Methylprednisolone

## Solu-Medrol inj 40mg

| 藥物代碼 | ISOLM |
| :--- | :--- |
| 適應症 | Adjunctive therapy in life-threatening conditions ,Rheumatic disorders , Multiple sclerosis ,Glomerulonephritis, lupus nephritis,SLE |
| 副作用 | GI upsets, aseptic necrosis of femoral & humeral heads; peptic ulceration with possible perforation & hemorrhage; manifestations of latent diabetes mellitus; anaphylactic reactions with or without circulatory collapse, cardiac arrest or arrhythmias, bronchospasm. Fluid & electrolyte disturbances. Also see lit. |
| 禁忌 | Systemic fungal infection |
| 藥物保存方式 | 室溫 |
| 用法用量 | Adjunctive therapy in life-threatening conditions 30 mg/kg for 30 mins, may be repeated every 4-6 hr up to 48 hr. Rheumatic disorders 1 g/day for 1-4 days or 1 g/mth for 6 months. SLE 1 g/day for 3 days. Multiple sclerosis 1 g/day for 3 or 5 days. Glomerulonephritis, lupus nephritis 30 mg/kg every other day for 4 days or 1 g/day for 3, 5 or 7 days. |
| 肝功能異常 | 無需調整劑量  pulsed IV methylprednisolone\(通常劑量為每日1 G \)可能會導致藥物性肝損傷如急性肝炎 |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 除非治療上需要 |
| 孕期用藥建議 | N/A |
| 附帶說明 | Methylprednisolone is classified as a nonfluorinated corticosteroid. When systemic corticosteroids are needed in pregnancy for rheumatic disorders, nonfluorinated corticosteroids are preferred. Chronic high doses should be avoided \(ACR \[Sammaritano 2020\]\).\( UpToDate\) 2021/0125 |
| 哺乳期用藥建議 | Unknown 尚未建立 |
| 附帶說明 | Corticosteroids are generally considered acceptable in breastfeeding women when used in usual doses; however, monitoring of the breastfeeding infant is recommended \(WHO 2002\). Methylprednisolone is classified as a nonfluorinated corticosteroid; when systemic corticosteroids are needed in a lactating woman for rheumatic disorders, low doses of nonfluorinated corticosteroids are preferred \(ACR \[Sammaritano 2020\]\).\( UpToDate\) 2021/0125 |
| 注射劑給藥建議途徑 | IM, IVD, IVP, IVPUSH |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | 【D5NS】 可選 仿單建議  【D5W】 可選 仿單建議  【N/S】 可選 仿單建議 |
| IVP 用法建議 | IV push over 1 minute |
| IVD 用法建議 | Low dose \(eg, &lt;1.8 mg/kg or &lt;125 mg/dose\): Administer over 3 to 15 minutes Moderate dose \(eg, &gt;2 mg/kg or 250 mg/dose\): Administer over 15 to 30 minutes High dose \(eg, &gt;15 mg/kg or &gt;500 mg/dose\): Administer over 30 to 60 minutes |
| 注意事項 | UpToDate:Do not administer moderate- or high-dose IV push; severe adverse effects, including hypotension, cardiac arrhythmia, and sudden death, have been reported in patients receiving high-dose methylprednisolone IV push over &lt;20 minutes. |

## Methylprednisolone 4mg

| 藥物代碼 | OMEPR |
| :--- | :--- |
| 適應症 | RA, acute & subacute bursitis, exfoliative dermatitis, allergic rhinitis, bronchial asthma, contact dermatitis & allergic conjunctivitis. |
| 副作用 | Fluid & electrolyte disturbances; muscle weakness, aseptic osteonecrosis, osteoporosis; peptic ulcer with perforation, hemorrhage, abdominal distention, impaired wound healing; increased intraocular pressure; Cushingoid state, growth suppression, menstrual irregularities, posterior subcapsular cataracts. |
| 禁忌 | Systemic fungal infection; immunization. Lactation |
| 藥物保存方式 | 室溫 |
| 用法用量 | Should be taken with food 4-48 mg once-qid. |
| 肝功能異常 | 無需調整劑量  肝硬化,脂肪肝患者應謹慎投與 |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 除非治療上需要 |
| 孕期用藥建議 | N/A |
| 附帶說明 | Methylprednisolone is classified as a nonfluorinated corticosteroid. When systemic corticosteroids are needed in pregnancy for rheumatic disorders, nonfluorinated corticosteroids are preferred. Chronic high doses should be avoided \(ACR \[Sammaritano 2020\]\).\( UpToDate\) 2021/0125 |
| 哺乳期用藥建議 | Unknown 尚未建立 |
| 附帶說明 | Corticosteroids are generally considered acceptable in breastfeeding women when used in usual doses; however, monitoring of the breastfeeding infant is recommended \(WHO 2002\). Methylprednisolone is classified as a nonfluorinated corticosteroid; when systemic corticosteroids are needed in a lactating woman for rheumatic disorders, low doses of nonfluorinated corticosteroids are preferred \(ACR \[Sammaritano 2020\]\).\( UpToDate\) 2021/0125 |
| 注射劑給藥建議途徑 | N/A |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

